CWC
RARE icon

Carolinas Wealth Consulting’s Ultragenyx Pharmaceutical RARE Stock Holding History

Carolinas Wealth Consulting’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11
Closed -$1K – 1003
2020
Q3 		$1K Buy
+11
New +$912 ﹤0.01% 873

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Carolinas Wealth Consulting's RARE Position: Q4 2020 in Review

Carolinas Wealth Consulting sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2020, closing a stake of 11 shares — an estimated $1K sold.

Carolinas Wealth Consulting first reported a position in RARE in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 252 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

  • Carolinas Wealth Consulting reported no remaining Ultragenyx Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 11 Ultragenyx Pharmaceutical shares in Q4 2020, an estimated $1K.
  • Carolinas Wealth Consulting first reported a position in Ultragenyx Pharmaceutical in Q3 2020 and held it in 1 quarter.
  • Carolinas Wealth Consulting's Ultragenyx Pharmaceutical position peaked at $1K in Q3 2020.
  • 252 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2020, filed 16 Feb 2021.